Recombinant Human DEFa1B Protein，His

DEFa1B, a member of the defensin family, is a small cationic peptide known for its antimicrobial properties and role in the immune response. Research on DEFa1B has gained significant interest due to its potential applications in therapeutic settings, particularly for its ability to combat various pathogens and its involvement in inflammation and host defense mechanisms. As a defensin, DEFa1B is characterized by its unique structural features, which include a compact fold stabilized by disulfide bonds, allowing it to interact effectively with microbial membranes. Studies have indicated that DEFa1B exhibits broad-spectrum antimicrobial activity, making it a promising candidate for drug development, especially amidst rising antibiotic resistance. Furthermore, understanding the mechanism of action of DEFa1B could lead to the design of novel peptide-based therapeutics. Investigations focus not only on its antimicrobial functions but also on how it modulates the immune response, which could have implications for autoimmune diseases and cancer therapy. The recombinant expression of DEFa1B has facilitated advanced studies and has opened up avenues for engineering variants with enhanced properties. Overall, the research surrounding DEFa1B is pivotal as it bridges microbiology, immunology, and pharmacology, aiming to leverage natural peptides for innovative health solutions.